RxDoctor Payments Data

Leilani Weaver

Nurse Practitioner · Colfax, WANPI 1316515943

Payments from drug & device makers

$363in general payments, 2019–2025

Across 16 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$80
  • Lilly USA, LLC$51
  • Novo Nordisk$45
  • Regeneron Healthcare Solutions, Inc.$44
  • Boehringer Ingelheim$34
  • Exact Sciences$28
  • plus $82 from 4 others

What the payments were for

  • Food & beverage$363100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$363 in reported general payments places this provider in the 80th percentile of 2,466 nurse practitioner providers in Washington.

See all nurse practitioner providers in Washington

Medicare billing

Part B allowed, 2024
$710
Medicare patients
12
Services billed
23

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide47$50,535
OzempicSemaglutide29$45,398
FarxigaDapagliflozin Propanediol50$41,000
JardianceEmpagliflozin22$19,459
EliquisApixaban20$14,528
XareltoRivaroxaban21$13,591
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,509
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,970
Breo ElliptaFluticasone/Vilanterol16$7,115
Synjardy XrEmpagliflozin/Metformin Hcl11$6,950
MyrbetriqMirabegron11$4,850
Incruse ElliptaUmeclidinium Bromide13$4,689
Novolog FlexpenInsulin Aspart11$3,617
Varenicline Tartrate15$3,556
Levothyroxine Sodium232$3,132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$51$50,53547 claims
Novo NordiskOzempic$45$45,39829 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$17$28,28358 claims
Boehringer IngelheimJardiance, Synjardy Xr$34$26,40933 claims
PfizerEliquis$26$14,52820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,466 nurse practitioner providers in Washington.

Other nurse practitioner in Colfax

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →